See the DrugPatentWatch profile for Xalkori
What does “Xalkori loss of exclusivity” mean?
“Loss of exclusivity” is the point when Xalkori (crizotinib) no longer has legal or regulatory exclusivity protections that keep generic or biosimilar versions from entering the market. After that date, other manufacturers may be able to sell competing products, assuming they meet the regulatory requirements for approval.
When does Xalkori’s exclusivity end?
The exact “loss of exclusivity” date depends on which kind of exclusivity you mean (for example, patent expiry versus regulatory exclusivity tied to approvals) and on the country or region (U.S. vs. EU vs. other markets). The provided information doesn’t include the specific date(s), so the precise timeline can’t be confirmed here.
What happens after exclusivity ends?
Once Xalkori’s exclusivity protections end, competing manufacturers can typically pursue approval pathways that allow them to bring lower-cost alternatives to market (such as generics, depending on patent status and regulatory pathway). This can reduce prices and increase prescribing options, but the competitive impact depends on whether any remaining patents still block specific generic products.
Does loss of exclusivity automatically mean generics arrive immediately?
Not necessarily. Even after “loss of exclusivity,” remaining patents (including method-of-use or formulation patents) can still delay entry for some competitors. Entry timing also depends on how quickly manufacturers file for approval and how regulators handle patent-related litigation or stay provisions.
Where can Xalkori exclusivity dates vary most?
Dates can vary based on:
- Jurisdiction (U.S. vs. EU vs. other regions)
- Whether the exclusivity is tied to the original approval or later labeled indications
- Whether patents remain in force for specific claims
What should I look up to get the correct Xalkori loss-of-exclusivity date?
To find the right date for your purpose, you usually need to check the latest listings for:
- Patent expiry for crizotinib in the relevant jurisdiction
- Regulatory exclusivity periods for the specific indication(s)
- Any patent litigation or settlements that affect launch timing
Sources: You’ll typically use official patent/exclusivity databases and regulatory agency listings for the exact dates.
If you tell me your country and indication, I can narrow the answer
If you share the country/region (e.g., U.S.) and which Xalkori indication you mean (original indication vs. later line/biomarker expansion), I can help pinpoint which exclusivity type and what date is most relevant.